ZIOPHARM Oncology Completes Enrollment in PICASSO 3 Trial
ZIOPHARM Oncology (NASDAQ: ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced Saturday completion of enrollment of the PICASSO 3 trial, an international, randomized, double-blind, placebo-controlled Phase 3 clinical study of palifosfamide in combination with doxorubicin, versus doxorubicin alone, for the treatment of metastatic soft tissue sarcoma in the front-line setting. Doxorubicin is the current standard of care for the treatment of STS in the front-line setting.
The PICASSO 3 study is designed to evaluate the safety and efficacy of palifosfamide and doxorubicin compared to doxorubicin and placebo, with no crossover between study arms. Progression-free survival is the primary endpoint for accelerated approval, with overall survival as the primary endpoint for full approval. PICASSO 3 is being conducted at more than 150 clinical centers in North America, Europe, South America, Australia, Israel and Asia. Based on current projections, the Company expects data for the study's primary endpoint for accelerated approval in the second half of this year.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.